TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06393556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality experience
Description: An immersive VR experience, delivered using a VR head-mounted display, of the real-world environment at the hospital, featuring the pre-operative admission suite, pre-anesthetic bay, operating theatre, postoperative recovery room, and medical staff.
Study: NCT01030640

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose of the drug formulation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tanezumab
Description: single dose of the active drug tanezumab at a dose level of 20 mg
Study: NCT01779791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765 (Ibrutinib)
Description: 560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.
Study: NCT00165802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7974
Description: Maximum Tolerated Dose defined as 0.45 mg/m\^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
Study: NCT03099174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort D) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
Study: NCT04068441

Intervention type: OTHER
Intervention: no intervention
Description: No intervention

Intervention type: OTHER
Intervention: no intervention
Description: No intervention
Study: NCT02841033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression or inability to tolerate.
Study: NCT04890873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERX1000
Description: ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A suspension containing magnesium hydroxide carbonate in polysorbate
Study: NCT01707420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: The active comparator, Gabapentin, is a structural analog of g-aminobutyric acid which has anticonvulsant properties. This study is a prospective randomized double-blinded trial examining the effectiveness of a single dose of liquid Gabapentin given 60 minutes prior to surgery for pain management in pediatric tonsillectomy/adenoidectomy pediatric patients.
Study: NCT04171739

Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole oral solution
Description: 200 mg once daily on Days 6 to 15
Study: NCT01707420

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liquid placebo
Description: Subjects randomized to the liquid placebo will receive an identical appearing liquid placebo of 0.4mL/kg.
Study: NCT00485472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: 50 or 100mg tablet, 400mg daily, for 12 weeks
Study: NCT04171739

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin Oral Capsule
Description: 600 mg once daily on Days 6 to 15

Intervention type: DRUG
Group type: OTHER
Intervention: Olorofim
Description: Single oral dose on Days 1 and 11

Intervention type: DRUG
Group type: OTHER
Intervention: Olorofim
Description: Single oral dose on Days 1 and 11
Study: NCT04266535

Intervention type: DEVICE
Intervention: Target controlled infusion
Description: Target controlled infusion vs manually controlled infusion

Intervention type: DEVICE
Intervention: Target controlled infusion
Description: Target controlled infusion vs manually controlled infusion
Study: NCT03798288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: selfBACK
Description: Participants will use the selfBACK system and app in addition to receiving usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will receive usual care
Study: NCT00135629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).
Description: Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Placebo Injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venepuncture: 100ml blood sample taken on 12 separate visits
Description: Venepuncture: 100ml blood sample taken on 12 separate visits

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Venepuncture: 100ml blood sample taken on 12 separate visits
Description: Venepuncture: 100ml blood sample taken on 12 separate visits
Study: NCT03611699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Umeclidinium / Vilanterol Dry Powder Inhaler
Description: umeclidinium/vilanterol dry powder inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaler
Study: NCT02669979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Professional oral care
Study: NCT04665869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined balance and brisk walking training
Description: 6-months of combined balance and brisk walking training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility and strengthening exercise
Description: 6-months of flexibility and strengthening exercise
Study: NCT00485472

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 or 100mg tablet, 400mg daily, for 12 weeks, matched to Lacosamide
Study: NCT02144753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NTX-1
Description: Investigational NTX-1 fiber to be taken as three (6g each) packets of the fiber per day, one 8g packet in the morning (one hour before eating breakfast) and the other two 8g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: psyllium (15 g)
Description: Psyllium (an over-the-counter fiber) to be taken as three (5g each) packets of the fiber per day, one 5g packet in the morning (one hour before eating breakfast) and the other two 5g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
Study: NCT03680937

Intervention type: OTHER
Intervention: Gavi , Merck® (automated vitrification instrument)
Description: Gavi, Merck ® permits semi-automated vitrification with closed system.
Study: NCT01463761

Intervention type: DEVICE
Intervention: ANS activity
Description: This ANS activity is measured by nocturnal heart rates records with Holter ECG.
Study: NCT01518439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha 200®
Description: inspiratory capacity is increased with the use of constant pressure device: Alpha 200®

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha 200® + physiotherapist
Description: inspiratory capacity is increased with the use of constant pressure device (Alpha 200®) combined with the manual pressures techniques to increase cough by the physiotherapist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough Assist®
Description: increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough Assist® + physiotherapist
Description: increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®) combined with the manual pressures techniques to increase cough by the physiotherapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapist
Description: manual pressures techniques to increase cough applied by the physiotherapist
Study: NCT01609322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity, Balance, Learning, and Exposure
Description: An in-home intervention that integrates exposure therapy with cognitive restructuring, exercise, and a home safety evaluation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fall prevention education
Description: In-home, individual sessions with a health educator regarding fall prevention
Study: NCT01639222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium 500 mg and Vitamin D3 800 IU
Description: Calcium 500 mg and Vitamin D3 800 IU chewable tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low calcium meals
Description: A normal Western European diet with reduced calcium content (400 mg per day).
Study: NCT04305782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Release/Relock Socket - In Lab
Description: The participants will operate the test socket in one of two test conditions: (1) pin re-lock before panel re-lock and (2) panel re-lock before pin re-lock. Participants will test each of the two conditions in a random order, in lab, following a structured protocol. Tests will determine if the order of the re-lock mechanisms influences changes in limb volume.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Release/Relock Socket - In Lab
Description: The participants will operate the test socket in one of two test conditions: (1) pin re-lock before panel re-lock and (2) panel re-lock before pin re-lock. Participants will test each of the two conditions in a random order, in lab, following a structured protocol. Tests will determine if the order of the re-lock mechanisms influences changes in limb volume.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Release/Relock Socket - Out of Lab
Description: The participants will operate the test socket in one of two test conditions: (1) pin re-lock before panel re-lock and (2) panel re-lock before pin re-lock. Participants will test each of the two conditions in a random order, out of lab, with no structured protocol. Tests will determine if the order of the re-lock mechanisms changes participant experience.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Release/Relock Socket & Control
Description: The participants will operate the test socket in one of two test conditions: (1) release/relock mechanisms enabled and (2) release/relock mechanisms disabled. Participants will test each of the two conditions in a random order, out of lab, with no structured protocol. Tests will determine how the novel release/relock mechanisms compare against traditional socket release methods.
Study: NCT03827174

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Return To Work Coordination
Description: External and internal coordination regarding sick leave. Establishment of a common return to work plan between employer och employee.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Return To Work Coordination
Description: External and internal coordination regarding sick leave. Establishment of a common return to work plan between employer och employee.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour Change Ability Program
Description: 1. Return to work coordination~2. Education for employers and employees in pain neuroscience, validation and problem-solving.~3. Patient-specific goal setting for return to work~4. Exercise and behavioural skills training related to return to work
Study: NCT03430830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 50mg
Description: 50mg, Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 50mg
Description: 50mg, Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 50mg
Description: 50mg, Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 50mg
Description: 50mg, Tablet
Study: NCT03430830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 50mg
Description: 50mg, Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 50mg
Description: 50mg, Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 200mg
Description: 200mg, Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 200mg
Description: 200mg, Tablet
Study: NCT03680937

Intervention type: OTHER
Intervention: Vitrification
Description: Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).

Intervention type: OTHER
Intervention: Vitrification
Description: Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).
Study: NCT04301427

Intervention type: OTHER
Group type: OTHER
Intervention: Bone mineral density
Description: Bone mineral density will be measured twice in all included patients.
Study: NCT04639323

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic ruler
Description: Endoscopic ruler for varices in portal hypertension~Product uses: measuring the diameter of the veins under the endoscopy for the assessment of the risk of variceal haemorrhage in patients with portal hypertension~Black and white measuring rule is highly recognizable under the endoscopy~The width of each cell is 1 mm, and the measuring range is 0-10 mm~With smooth edge, safe and reliable
Study: NCT05567523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: In dexmedetomidine groups, patients will be pumped 0.1ml/kg of dexmedetomidine (contained dexmedetomidine 0.25/0.5/0.75µg/kg in Group D0.25/D0.5/D0.75) for 15min before anesthesia induction, following continuous infusion at the rate of 0.125ml/kg/h until the end of operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: midazolam
Study: NCT00838591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-221
Description: Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03430830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 200mg
Description: 200mg, Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 200mg
Description: 200mg, Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 200mg
Description: 200mg, Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 200mg
Description: 200mg, Tablet
Study: NCT02078986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Electromyostimulation
Description: Supervised WB-EMS, 3 sessions in 2 weeks (1,5 sessions/week) for 14 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Resistance Exercise Training
Description: Supervised High Intensity Resistance Exercise Training (HIT) 2-3 sessions/week for 14 weeks
Study: NCT03786822

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon Pulmonary Vein Isolation - PVI
Description: A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12 French steerable sheath (FlexCath, Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon Pulmonary Vein Isolation - PVI
Description: A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12 French steerable sheath (FlexCath, Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
Study: NCT01884090

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Youth Empowerment Solutions (YES)
Description: Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Empowerment Solutions (YES)
Description: Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
Study: NCT03583593

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DIAMEL
Description: Diamel is administered 6 capsules a day divided into three doses that are ingested before each meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered 6 capsules a day divided into three doses that are ingested before each meal.
Study: NCT04258150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 6 mg/kg IV q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg IV twice q6w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg/kg IV q4w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: * A total dose of 15 Gy as a single fraction is prescribed as the mean dose to the PTV.~* PTV should be covered by 95% isodose (PTV D99% \> 95%).
Study: NCT02763085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basic Filling Material
Description: Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques.
Study: NCT02968056

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency energy is used for ablation in both arms of this study (Hybrid group and MIS group)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Radiofrequency energy is used for ablation in both arms of this study (Hybrid group and MIS group)
Study: NCT02710955

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thickened infant formula
Study: NCT02917057

Intervention type: DRUG
Intervention: exenatide once weekly
Description: Exenatide treatment in customary clinical care in the USA

Intervention type: DRUG
Intervention: basal insulin
Description: basal insulin tretament in the customary clinical care in USA
Study: NCT02605291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet with a different macronutrient content A
Description: A diet with altered macronutrient content will be provided to participants on days 4-6 of experimental arm 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet with a different macronutrient content B
Description: A diet with a different macronutrient content compared to arm 1 will be provided to participants on days 4-6 of experimental arm 2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet with a different macronutrient content C
Description: A diet with a different macronutrient content compared to arms 1 and 2 will be provided to participants on days 4-6 of experimental arm 3.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval treadmill running exercise
Description: Participants will perform interval treadmill running exercise on days 4 and 5 of all experimental arms.
Study: NCT00537979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol injection
Description: Most recent iPTH level in pg/mL divided by 100 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol capsules
Description: Most recent iPTH level in pg/mL divided by 80 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
Study: NCT02414152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra
Description: 100mg of anakinra adminstered by a subcutaneous injection for a minimum of 28 days, retreatment with additional 28 day cycle based on clinical response
Study: NCT00560443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac
Description: 0,5 mg/kg per os one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tramadol
Description: 2,5 mg/ kg per os in one dose
Study: NCT00493831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine polacrilex, transdermal system or inhaler
Description: on label use of Nicotine replacement therapy (NRT)
Study: NCT02605291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval treadmill running exercise
Description: Participants will perform interval treadmill running exercise on days 4 and 5 of all experimental arms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval treadmill running exercise
Description: Participants will perform interval treadmill running exercise on days 4 and 5 of all experimental arms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steady state treadmill running exercise
Description: Participants will perform steady state treadmill running exercise on day 7 of all experimental arms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steady state treadmill running exercise
Description: Participants will perform steady state treadmill running exercise on day 7 of all experimental arms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steady state treadmill running exercise
Description: Participants will perform steady state treadmill running exercise on day 7 of all experimental arms.